安旭生物(688075) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥111,765,659.39, a decrease of 43.16% compared to the same period last year[4] - Net profit attributable to shareholders was ¥20,064,621.75, down 92.12% year-over-year[4] - The net profit excluding non-recurring gains and losses was ¥10,954.24, a decline of 100% compared to the previous year[4] - Basic earnings per share were ¥0.16, down 94.30% from the same period last year[4] - Total revenue for the first three quarters of 2023 was CNY 316,140,350.49, a significant decrease from CNY 6,126,614,488.82 in the same period of 2022, representing a decline of approximately 94.84%[20] - Net profit for Q3 2023 was CNY 186,362,914.02, a sharp decline compared to CNY 3,131,740,429.19 in Q3 2022, reflecting a decrease of approximately 94.03%[22] - Basic and diluted earnings per share for Q3 2023 were both CNY 1.47, down from CNY 34.51 in Q3 2022, indicating a decline of about 95.74%[23] Cash Flow and Liquidity - Cash flow from operating activities was negative at ¥-684,387,106.20, a decrease of 117.39% year-to-date[4] - The cash and cash equivalents decreased significantly to approximately ¥724.35 million from ¥2.14 billion, indicating a reduction of approximately 66.1%[16] - The company reported a total cash inflow from operating activities of 565,921,380.07 RMB in the first three quarters of 2023, compared to 6,587,653,959.61 RMB in the same period of 2022[24] - The cash inflow from investment activities in the first three quarters of 2023 was 5,903,864,230.10 RMB, down from 8,055,905,733.37 RMB in the same period of 2022[24] - The company experienced a cash outflow of 436,308,925.70 RMB from financing activities in Q3 2023, compared to 240,401,565.59 RMB in Q3 2022[25] Research and Development - Total R&D investment for the period was ¥19,670,180.53, a reduction of 46.17% compared to the previous year[5] - R&D investment accounted for 17.60% of revenue, a decrease of 5.28 percentage points year-over-year[5] - Research and development expenses for Q3 2023 were CNY 68,008,768.32, significantly lower than CNY 690,730,825.03 in Q3 2022, a reduction of approximately 90.14%[21] Assets and Liabilities - Total assets at the end of the period were ¥5,881,883,494.58, a decrease of 15.27% from the end of the previous year[5] - As of September 30, 2023, the company's total current assets amounted to approximately ¥4.94 billion, a decrease from ¥6.21 billion at the end of 2022, representing a decline of about 20.4%[16] - Total liabilities decreased to CNY 729,910,494.29 in Q3 2023 from CNY 1,522,910,864.17 in Q3 2022, reflecting a reduction of approximately 52.00%[18] - The company reported a total equity of CNY 5,151,973,000.29 in Q3 2023, down from CNY 5,418,771,342.16 in Q3 2022, indicating a decrease of about 4.93%[18] Market and Shareholder Information - The company plans to continue expanding its market presence and invest in new product development to drive future growth[12] - The top shareholder, Hangzhou Aixi Holding Co., Ltd., holds 26.87% of the shares, followed by Ling Shisheng with 25.12%[12] - As of the report date, the company had a total of 8.498 million shareholders, indicating a broad base of investor interest[11] Sales and Demand - The company experienced a significant decline in demand for its testing products due to the end of the global respiratory infectious disease, leading to a substantial drop in sales revenue[9] - Total operating costs for the first three quarters of 2023 were CNY 215,762,189.99, down from CNY 2,303,979,044.39 in 2022, indicating a reduction of about 90.65%[20] Investment Income - The company recorded an investment income of CNY 117,560,589.06 in Q3 2023, compared to CNY 29,180,482.34 in Q3 2022, representing an increase of about 303.73%[21] - The company reported a significant increase in cash received from investment income, totaling 88,666,071.81 RMB in 2023 compared to 38,353,152.29 RMB in 2022[24]